Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teriparatide and Zoledronic Acid in Osteogenesis Imperfecta
NCT03735537Phase 4Completed
- Sponsor
- University of Edinburgh
- Start
- Nov 2016
- Primary completion
- Feb 2025
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 2
01
Overview
A Phase 4 trial of teriparatide, zoledronic acid in osteogenesis imperfecta (OI), sponsored by University of Edinburgh. Started Nov 2016; status: completed.
02
Drugs
teriparatidezoledronic acid
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on NCT03735537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03735537.